# Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

> **NCT05181995** · PHASE2,PHASE3 · TERMINATED · sponsor: **Aptinyx** · enrollment: 121 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** NYX-783
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05181995
- **Lead sponsor:** Aptinyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-13
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** company decision
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181995, "Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05181995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*